VitaNova Life Sciences Corporation
VNOV
$2.38
$1.0072.46%
OTC PK
| 04/30/2026 | 01/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 151.54% | 66.14% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 151.54% | 66.14% | |||
| Cost of Revenue | 286.52% | 136.50% | |||
| Gross Profit | -16.31% | 21.28% | |||
| SG&A Expenses | 38.91% | 66.83% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 185.83% | 102.17% | |||
| Operating Income | -335.33% | -52.92% | |||
| Income Before Tax | -329.12% | -52.97% | |||
| Income Tax Expenses | -236.66% | 43.46% | |||
| Earnings from Continuing Operations | 139.41% | -224.02% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 139.41% | -224.02% | |||
| EBIT | -335.33% | -52.92% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 139.62% | -223.26% | |||
| Normalized Basic EPS | -328.57% | -52.70% | |||
| EPS Diluted | 139.62% | -223.26% | |||
| Normalized Diluted EPS | -328.57% | -52.70% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||